Erythropoietin Stimulating Agents Policies
CMS has policies that effect the use of Erythropoietin Stimulating Agents in ESRD facilities. To find out more, click on the links below.
ESA Monitoring Policy, Effective October 1, 2006 (PDF)
ESA Monitoring Policy, Effective April 1, 2006 (PDF)
Chapter 11 - End Stage Renal Disease (ESRD) (PDF)
Chapter 8 - Outpatient ESRD Hospital, Independent Facility, and Physician/Supplier Claims (PDF)